Tag: Staphylococcus Aureus

APHB: SUCCESSFUL CASE REPORTS PRESENTED FOR AB-SA01 AND AB-PA01

Multiple Case Reports Presented for Patients Treated with AB-SA01 and AB-PA01



On June 7, 2018, AmpliPhi Biosciences Corp. (NYSE:APHB) reported that multiple case reports on patients treated with the company’s lead bacteriophage development products, AB-SA01 and AB-PA01, were presented at the American Society of Microbiology (ASM) Annual Meeting and the 41st European Cystic Fibrosis Conference. Topline results from these cases had previously been announced by AmpliPhi with the presentations providing additional details.

At ASM, a presentation described four cases of severe Staphylococcus aureus infection treated with AB-SA01. Three of the cases involved patients with endovascular infection and one case of severe vertebral osteomyelitis with epidural abscess. For all the patients, medical and surgical therapy options had been exhausted. Patients were treated with 3×109 plaque-forming units of AB-SA01 intravenously twice-daily for two weeks in combination with the best antibiotic therapy available. The bacteriophage therapy was well tolerated in all patients with no reports of serious adverse events … read more

AmpliPhi Biosciences Will Utilize NIAID Preclinical Services to Advance

Development of Its Targeted Therapeutic Candidate for the Treatment of Resistant Staphylococcus Aureus

 

SAN DIEGO–(BUSINESS WIRE)–AmpliPhi Biosciences Corporation (NYSE American: APHB), a clinical-stage biotechnology company focused on precisely targeted bacteriophage therapeutics for antibiotic-resistant infections, today announced that it will utilize the Therapeutic Development Services funded by the National Institute of Allergy and Infectious Disease (NIAID), part of the National Institutes of Health (NIH), to conduct further preclinical studies of AB-SA01. The Therapeutic Development Services program funds the provision of preclinical services for selected companies and researchers in order to advance development of promising interventional agents.

 

“We are pleased and encouraged by the support from the NIAID and its commitment to studying the role of bacteriophage in combating infectious diseases,” said Paul C. Grint, M.D., CEO of AmpliPhi Biosciences. “This service will help support the development of bacteriophages as a much needed treatment for antibiotic-resistant infections.”

 

AB-SA01 is a 3-phage investigational therapeutic being developed for treatment of serious and drug-resistant Staphylococcus aureus (S. aureus) infections. In preclinical studies, AB-SA01 demonstrated broad activity against more than 96% of global S. aureus clinical isolates, including multidrug-resistant forms. AB-SA01 has completed two Phase 1 studies and has also been administered to patients under compassionate use guidelines in the U.S. and Australia for treatment of serious and life-threatening S. aureus infections … read more